
Pierre Fabre amends license agreement with Puma Biotechnology
According the extended agreement, Pierre Fabre may not only market the breast cancer recurrence blocker Nerlynx® (neratinib) within Europe and...

Researchers identify CTLA-4 response marker
The research team headed by Simon Heideger and Hendrick Poeck from Technical University of Munich together with colleagues from Memorial Sloan...

Zelluna Immunotherapy and Glycostem Therapeutics in licence deal
TCR cell therapy specialist Zelluna Immunotherapy (Oslo) and NK cell manufacturing specialist Glycostem Therapeutics BV (Oss) have entered into a...

PFF Group NV acquires stake in Autolus Therapeutics
With the investment into London-headquartered Autolus Therapeutics, PPF Group N.V. significantly increased its commitment to the healthcare sector....

Protein protects against liver fibrosis
In mice, a team headed by Philipp Lang from University Düsseldorf, Germany, showed that the iRhom2 protein counteracted the injury- and...

EMA greenlights new medicines
With the three innovative medicines and four generics the number of recommended medicines raised to 47 in 2019. The Committee saw a positive...

Sanofi buys Synthorx Inc for US$2.35bn
Sanofi SA‘s and Synthorx Inc's Boards approved the deal which forsees that Sanofi will acquire all of the outstanding shares of Synthorx for $68 per...